Heme alkylation by the antimalarial drug artemisinin is reported in vivo, within infected mice that have been treated at pharmacologically relevant doses. Adducts resulting from the alkylation of heme by the drug were characterized in the spleen of treated mice, and their glucuroconjugated derivatives were present in the urine. Because these heme-artemisinin adducts were not observed in noninfected mice, this report confirms that the alkylating activity of this antimalarial drug is related to the presence of the parasite in infected animals. The identification of heme-artemisinin adducts in mice should be considered as the signature of the alkylation capacity of artemisinin in vivo.
alkylation ͉ malaria ͉ trioxane S ince the beginning of the last decade, many research groups have been working on the mechanism of action of antimalarial drugs and have prepared new drug candidates to fight against the comeback of this parasitic disease (1) (2) (3) . Many strains of Plasmodium falciparum, responsible for severe malaria, have become resistant to classical drugs like chloroquine (4) . Quinoline-based drugs (quinine and chloroquine) are able to inhibit, via a strong stacking, the aggregation of heme liberated during the digestion of hemoglobin by the parasite into the redox inactive hemozoin (5) . The mechanism of action of artemisinin, a nonquinoline antimalarial drug containing a 1,2,4-trioxane motif (1, Fig. 1 ), has been the matter of intense debates for the last decade (6) (7) (8) (9) (10) .
Among the different hypotheses on the mechanism of action of artemisinin, one concerns the reductive activation of its endoperoxide function by the iron(II) center of free heme, generating a C4-centered radical that alkylates the meso positions of protoporphyrin-IX (2, Fig. 1 ) (11) (12) (13) (14) (15) . Many antimalarial trioxanes are also able to alkylate heme or heme models (8, 16, 17) .
Is the formation of heme-artemisinin adducts a laboratory curiosity or is it biologically relevant and related to the mechanism of action of the drug in vivo? We addressed this question by treating Plasmodium vinckei-infected mice with artemisinin at pharmacological doses by i.p. or oral route. The covalent adducts heme-artemisinin 2 and 3 were identified in the spleen of all treated mice. The hydroxylated and glucuroconjugated derivatives of heme-artemisinin adducts 4 and 5 were identified in the urine of treated mice. These adducts were not detected after treatment of healthy mice by artemisinin.
Materials and Methods
Chemicals. ␤-Glucuronidase from bovine liver (EC 3.2.1.31, type B-1, 1.24 ϫ 10 6 units͞g) was purchased from Sigma.
Animal Treatment. Female Swiss albino mice weighing 25-30 g were inoculated i.p. with 6 ϫ 10 7 erythrocytes parasitized with P. vinckei petteri strain. Parasitemia was determined by microscopic method on Giemsa thin blood smears. When it was higher than 40% (usually 3 days), animals were treated once, via i.p. or oral route, with artemisinin diluted in DMSO (100 l) at doses of 200 or 100 mg͞kg (i.p. route) or 100, 50, or 20 mg͞kg (oral route).
One lot of four infected mice was treated with artemisinin at 200 mg͞kg in 100 l of DMSO by i.p. route for urine analyses. Three lots of two, one, and one mice, respectively, were treated at 100 mg͞kg by i.p. route for urine and spleen analyses. Three lots (n ϭ 2 for each lot) were treated at 100, 50, and 20 mg͞kg, respectively, by oral route for urine and spleen analyses. For control experiments, infected mice received either no treatment, pure DMSO (100 l, n ϭ 2 by i.p. route, n ϭ 1 by oral route), or heme-artemisinin adducts 2 ϩ 3 (200 mg͞kg in 100 l of DMSO by i.p. route, n ϭ 2). Healthy mice were treated with artemisinin (200 mg͞kg, i.p. route, n ϭ 2; 100 mg͞kg, i.p. route, n ϭ 1; or 100 mg͞kg, oral route, n ϭ 1), adducts 2 ϩ 3 (200 mg͞kg, i.p. route, n ϭ 2), or pure DMSO (100 l, n ϭ 2 by i.p. route; n ϭ 1 by oral route). The spleens of healthy mice without any treatment (n ϭ 3) were also examined. Urine was collected by lot. Each spleen was analyzed individually.
Urine Treatment. Mice urine was collected for 7 h after treatment and aliquoted by 50 l of fractions. One fraction was diluted with a solution of ␤-glucuronidase (1,600 units) in CH 3 COONa, 100 mM, pH 5.2 (50 l), and allowed to stand at 37°C for 16 h. Two other fractions were diluted with CH 3 COONa 100 mM, pH 5.2 (50 l), and kept at either -20°C or 37°C for 16 h. Spleen Treatment. Spleen was removed 7 Ϯ 0.5 h after treatment. Each whole mouse spleen was crushed with sand in a mortar then extracted with glacial acetic acid (1 ml).
HPLC and Liquid Chromatography-MS (LC-MS)
Analyses. HPLC analyses were performed by using a 10-m C18 Nucleosil column (250 ϫ 4.6 mm). Eluents were (A) methanol͞water͞formic acid, 60͞40͞1, vol͞vol and (B) methanol͞water͞formic acid, 80͞20͞1, vol͞vol. The elution gradient was linear from A͞B ϭ 100͞0 to A͞B ϭ 0͞100 in 15 min, followed by 15 min at A͞B ϭ 0͞100. Flow rate was 1 ml͞min, and UV-Vis detection was at 406 nm.
MS Analyses. Positive-ion electrospray mass spectra were obtained by LC-MS by using an API 365 Sciex PerkinElmer instrument. The detection was scan mode (total ionic current) with a step size of 0.15 atomic mass units (amu) and scan range of 500-1,200 amu or single ion monitoring mode, with a dwell time of 150 msec for better sensitivity. Quantification of adducts 2 ϩ 3 was made by the following method: HPLC allowed quantification of 2 ϩ 3 ϩ heme-Cl (m͞z ϭ 898.5, 838.5, and 650.3, respectively), estimating that these hemin derivatives have similar extinction coefficients; the ratio 2 ϩ 3͞heme-Cl was then calculated from the relative intensities of the corresponding ionic currents, considering these two species have similar volatilities.
Hydrogen Peroxide-Mediated Chlorination of Heme. Hemin (3.5 mg, 5.4 mol) was incubated in DMSO (0.5 ml) with nBu 4 N ϩ Cl Ϫ (6 mg, 22 mol) and H 2 O 2 100 mM (10 l) for 30 min at room temperature. A new aliquot of H 2 O 2 was then added (10 l), and the solution was allowed to stand at room temperature for a further 30 min. For analysis, an aliquot of the reaction mixture was 10-fold diluted with glacial acetic acid.
Results and Discussion
When the parasitemia was as high as 40-75% (typically 3 days after infection), mice were treated once with artemisinin doses at 100 or 200 mg͞kg by i.p. route or at 20, 50, or 100 mg͞kg by oral route (solutions in DMSO, 100 l). These doses are within the range or below the curative dose of CD 50 ϭ 140 mg͞kg reported for artemisinin in the Rane test (single s.c. dose on day ϩ 3 after infection) (18) . Mice with the same treatment were then housed with a standard laboratory diet and gavaged with pure water (3 ϫ 200 l) after 1.5, 3.5, and 5.5 h. Urines were pooled for mice that had the same treatment and analyzed by LC-MS. After 7 Ϯ 0.5 h, mice were killed, and spleens were individually crushed, extracted with acetic acid, and analyzed by HPLC and LC-MS.
Covalent Adducts Heme-Artemisinin in the Spleen. The LC-MS analysis of the spleen extracts (without any additional treatment) of an infected mouse treated with artemisinin (100 mg͞kg, i.p. route) is reported in Fig. 2 . The ionic currents of m͞z ϭ 898.5 and 838.5, corresponding to heme-drug adducts 2 and 3, respectively, were detected along with unreacted heme (m͞z ϭ 616.3) (Fig. 2 b-d) . Compound 2 is a mixture of four regioisomers resulting from the alkylation of the four meso positions of heme by the C4-centered radical generated by the drug activation by iron(II)-heme, as described (8, (12) (13) (14) . For this reason, the ionic current of 2 appears as three partly resolved peaks having the same mass spectrum (R t ϭ 17.5, 18.2, and 19.3 min, m͞z ϭ 898.5, Fig. 2c ). Compound 3 (four regioisomers) appeared as two chromatographic peaks (R t ϭ 18.4 and 18.9 min, m͞z ϭ 838.5, Fig. 2d ). It is formed by intramolecular addition of the hydroxyl function at C12a onto the carbonyl at C10, followed by the loss of acetic acid and a transesterification process. A similar reaction has already been reported for heme alkylation by a C10-substituted artemisinin derivative (15) . The chromatographic behavior and mass spectra (including isotopic pattern) of adducts 2 and 3 detected in the mouse spleen were consistent with those of chemically prepared adducts. § In several spleen extracts, compound 3 is the major product and should be considered as a strong marker of the alkylation of heme by artemisinin in vivo. Adduct 3 was detected in the spleen of all infected mice treated either by oral or i.p. routes (number of mice ϭ six and three, respectively). It should be noted that the m͞z ϭ 838.5 ionic current was detected in the spleen of mice treated by oral route at doses as low as 50 and 20 mg͞kg (Fig. 3) , using single ion monitoring mode electrospray ionization (ESI) ϩ -MS. As control experiments, infected mice received pure DMSO (100 l, oral route), healthy mice received either no treatment, artemisinin (100 mg͞kg i.p. or oral routes), or pure DMSO (100 l, oral). In all control mice, compounds 2 and 3 were not detected. On the bases of HPLC and MS, the amount of heme-artemisinin adducts 2 ϩ 3 in the spleen of infected mice treated at 100 mg͞kg (i.p. route) was estimated to be 30 -100 nmol, corresponding to 0.4 -1.1% of the injected artemisinin dose. This value can be considered only as indicative.
In addition, it should be mentioned that all of the spleen extracts contained highly variable amounts of a compound with m͞z ϭ 650.3, which corresponds to a monochlorinated heme derivative [M(heme-HϩCl)] (Fig. 2e) . This product was present even in the spleen of healthy mice in the absence of any treatment. It is therefore not related to the disease or the treatment. This compound, named heme-Cl for short, is probably generated by a peroxidase-type reaction of heme not been described until now. ¶
Glucuroconjugated Derivatives of Heme-Artemisinin Adducts in Urine.
The urine of malaria-infected mice treated with artemisinin at 100 or 200 mg͞kg (i.p. route) or at 50 mg͞kg (oral route) was analyzed by LC-MS. Peaks corresponding to heme derivatives more polar than heme itself were evidenced (Fig. 4a) . Compounds 4 and 5 ( Fig. 1) have a blue-shifted absorption with respect to heme ( max ϭ 406 -408 nm, compared with 398 nm for heme), as observed for adducts 2 and 3. Their m͞z values were 1,090.5 and 1,030.5 amu, corresponding to the hydroxylated and glucuroconjugated derivatives of 2 and 3, respectively. When the artemisinin dose was 100 mg͞kg (i.p.), the quantity of heme-drug adducts in urine was 33-81 nmol, corresponding to 0.4 -0.9% of the injected artemisinin dose (evaluated by HPLC).
To confirm the identification of compounds 4 and 5, urine samples were treated with ␤-glucuronidase, known to cleave specifically 1␤-D-glucuronides, at 37°C for 16 h in an acetic acid medium (20) . Adducts 4 and 5 then disappeared by loss of a glucuronic acid unit, giving rise to less polar compounds with m͞z ϭ 914.5 and 854.5 amu (Fig. 4c) , which correspond to the expected hydroxylated heme-artemisinin adducts 6 and 7 (Fig. 1) .
As a control experiment, urine was heated under the same conditions but without ␤-glucuronidase (urine͞CH 3 COONa 100 mM, pH 5.2, 1͞1, vol͞vol, 37°C, 16 h). Under these conditions, adduct 4 was quantitatively transformed to 8 (m͞z ϭ 1,048.5), corresponding to the hydrolysis of the lactone function and loss of an acetic acid molecule (Fig. 1) . In addition, traces of adduct 9, corresponding to the loss of a glucuronic acid moiety from 8 (m͞z ϭ 872.5), were also detected (Fig. 4b) . However, in the presence of ␤-glucuronidase, this pathway 4 3 8 3 9 was always a minor route, as attested by trace amounts of adduct 9 (m͞z ϭ 872.5, not shown in Fig. 4c) .
The small quantities of hydroxylated and glucuroconjugated heme-artemisinin adducts obtained in these animal studies did § Heme-artemisinin adducts 2 ϩ 3 were prepared by a modified procedure of ref. 14, as follows: hemin was reacted with artemisinin in the presence of sodium dithionite in DMSO for 1 h at room temperature ([hemin] ϭ 18 mM, hemin͞artemisinin͞S2O4 2Ϫ molar ratio ϭ 1͞1͞1.4). Water was then added. The precipitate was centrifuged and washed with water. The recovered porphyrinic derivative was then dissolved in ethanol and reprecipitated by addition of hexane. Electrospray ionization (ESI) ϩ -MS analysis: 2 ϩ 3͞heme ϭ 93͞7; ratio 2͞3 ϭ 30͞70. The NMR analysis of the demetalated heme-artemisinin adducts confirm that 2 and 3 are mixtures of four regioisomers: see ref. 13 . (In different chromatographic conditions than those reported here, specially using a C4 column instead of C18, the four regioisomers of adduct 2 appear as four resolved chromatographic peaks; see ref. 19 .) ¶ To check the formation of heme-Cl through a peroxidase-type mechanism, hemin was incubated with hydrogen peroxide and n-tetrabutyl ammonium chloride (as chloride source) in DMSO. not allow NMR identification of the exact hydroxylation sites on these adducts. A heme-artemisinin adduct with glucuronidation at a heme carboxyl group should have m͞z ϭ 1,074.5, not 1,090.7. The m͞z value ϭ 1,090.7 is consistent only with hydroxylation ϩ glucuronidation. Such reaction cannot be excluded on a propionic -CH 2 -of heme. However, despite the fact that the urine of infected mice contained a large amount of free heme (m͞z ϭ 616.3, Fig. 4 ), heme derivatives having undergone glucuronidation at the carboxyl function (m͞z ϭ 792.5), hydroxylation (m͞z ϭ 632.3), or hydroxylation ϩ glucuronidation on a propionic -CH 2 -(m͞z ϭ 808.5) were never detected (the degradation of heme in animals is mediated by heme oxygenase via an oxidation at a meso position; see ref. 21 ). On the contrary, the artemisinin skeleton is known to undergo hydroxylation and glucuronidation in healthy rat and human (22) . The glucuronidation of heme-artemisinin adducts on the artemisinin-derived moiety is therefore the more likely pathway.
It was previously reported (22) that artemisinin derivatives injected into rats or humans undergo phase I hydroxylations at several positions by P450 enzymes, followed by phase II glucuroconjugation. Liver was the main organ of their metabolism. However, these studies were performed on healthy animals or patients, without the possibility of detecting products derived from the reactivity of artemisinin in malariainfected erythrocytes. Healthy mice were treated with artemisinin or chemically prepared adducts 2 ϩ 3 § (200 mg͞kg in 100 l of DMSO, i.p.), and malaria-infected mice were treated with adducts 2 ϩ 3 (200 mg͞kg in 100 l of DMSO) or with pure DMSO by i.p. route. In none of these control mice did the spleen and urine contain detectable amounts of adducts 2 and 3 or 4-9, respectively. This might be because of the poor absorption of adducts 2 and 3 when administered by i.p. route.
In the present work, the in vivo formation of hemeartemisinin adducts is strictly related to both the disease and the artemisinin treatment at curative doses. These adducts were not observed in healthy animals treated with artemisinin. Furthermore, nonmetabolized adducts 2 and 3 were detected in the spleen, the main organ involved in the elimination of damaged red blood cells.
Besides spleen and urine, several other organ extracts were analyzed by HPLC and͞or LC-MS. No heme-artemisinin adducts could be detected in liver, gall bladder, duodenum, and kidneys of malaria mice treated with artemisinin by i.p. route (100 mg͞kg). However, the presence of glucuroconjugated derivatives in the urine clearly indicates that these compounds have gone through liver and kidneys. But the metabolism of hemeartemisinin adducts formed in infected erythrocytes is a dynamic phenomenon and, among the analyzed organs, only the spleen retains adducts 7 h after treatment.
Conclusion
Because the alkylation of heme by artemisinin occurred only in infected mice treated at pharmacologically relevant doses, these heme-artemisinin adducts should be considered the signature of the strong alkylating capacity of this antimalarial drug. We have to keep in mind that such alkylating property of artemisinin is triggered by an iron(II) center; consequently, other parasitic iron-containing enzymes or proteins also have to be considered as potential activators of trioxane-based antimalarial drugs.
The results reported in this manuscript are the validation in animals of the concept of alkylating trioxanes used in the design of new antimalarial agents, including the dual molecules named trioxaquines (8, 23) . 
